Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant toxic shock syndrome toxin-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Next Previous
Drug Profile

Recombinant toxic shock syndrome toxin-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Alternative Names: BioMed rTSST-1 variant vaccine - Biomedizinische Forschungsgesellschaft; ORG 28077; rTSST-1 variant vaccine - Biomedizinische Forschungsgesellschaft

Latest Information Update: 14 May 2020

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biomedizinische Forschungsgesellschaft
  • Class Bacterial vaccines; Protein vaccines; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Bacterial infections

Most Recent Events

  • 06 Feb 2020 Phase II development is ongoing in Austria
  • 06 Feb 2020 Biomedizinische Forschungs completes a phase II trial in Bacterial infections (Prevention) in Austria (IM) (EudraCT2015-003714-24) (NCT02814708)
  • 01 Oct 2019 Discontinued - Phase-II for Bacterial infections (Prevention) in Austria (IM)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top